Mounjaro's September 2025 Price Increase: What Changed and What to Do Now

What Eli Lilly's official price change actually means for your monthly cost

Eli Lilly's UK price revision came into effect on 1 September 2025 and applied across the Mounjaro dose range, with the steepest movement at the higher strengths. Before the change, the 15mg pen carried a list price of roughly £122. After it, that same pen was listed at around £330, a figure reported across pharmacy trade press and consumer media at the time. Lower doses saw proportionally smaller increases, but the direction was consistent upward across the board.

Private providers set their own prices above the list price, accounting for dispensing, clinical oversight, delivery, and operating costs. That's why you'll see a range rather than a single number when you search: roughly £149 at the starter dose through to around £375 at the top end, depending on the clinic and what's actually included. The full picture of how Mounjaro is priced in the UK involves more variables than the headline figure suggests, and if you want to understand exactly what drove costs upward, our page on the Mounjaro price rise in September 2025 sets out the detail behind the change.

The NICE appraisal of tirzepatide (TA1026) confirmed its clinical value for eligible adults, that clinical case hasn't changed. What changed is what it costs to access privately, which means it's worth being clear about what you're actually paying for.

What headline prices often leave out, and why that gap matters after a list-price rise

A private Mounjaro price that looks low at first glance sometimes reflects only the pen. The consultation, prescription fee, delivery charge, and any dose-review or aftercare support may each appear as a separate line, or not appear at all until you're already a patient. When list prices rise steeply, providers absorbing that increase in a headline figure sometimes do so by trimming what's bundled in.

It's worth asking, before you commit, what you'd pay for a follow-up review if your dose needs adjusting, whether delivery is included or charged per order, and whether the consultation is genuinely clinical or largely automated. The NHS guidance on tirzepatide is clear that this is a prescription medicine requiring proper clinical assessment, that assessment has a real cost, and if it isn't visible in the price, it's worth asking where it went.

Aftercare matters more than it might seem at first. GI side effects are common in the first weeks of treatment, dose escalation requires clinical sign-off, and questions come up between appointments. A service that includes seven-day prescriber support is a different product from one that dispatches a pen and wishes you luck. You can read more about how treatment is structured on our Mounjaro overview page.

Where nume sits in this, and why we're not trying to be the cheapest option

We're going to be straightforward: cheapest isn't a race we entered. Our price is all-inclusive (consultation, prescription, the treatment, and free next-working-day delivery) and we've kept it that way deliberately rather than splitting things out to show a lower starting number. Since the September 2025 rise, that inclusive approach is, if anything, easier to justify, and our page covering the Mounjaro price increase in September explains why the saving from a stripped-back service is smaller than it once was, while what you're losing in clinical oversight remains the same.

Your order, once clinically approved, goes out the same day if submitted before 12pm Monday to Friday. It arrives via DPD the next working day, in plain, unbranded packaging, the tracking notification lands on your phone like any other parcel. There's nothing about the box that announces what's inside. Current treatment pricing is shown on our treatment page, alongside the consultation you'd need to start.

We don't run discount codes, promotional pricing, or seasonal offers. For a prescription medicine dispensed by a GPhC-registered pharmacy, that's a deliberate policy, not an oversight. You can see who leads our clinical team on the clinical team page if you'd like to know more about the prescribers involved.

The case for not optimising around price when the medicine is prescription-only

The MHRA has warned publicly about counterfeit weight-loss pens sold through social media and unverified online sellers. Large seizures of fake pens have taken place across the UK, and in October 2025 a domestic manufacturing site producing counterfeit tirzepatide pens was raided. Fake pens have been found to contain the wrong substances entirely. The common thread across cases: sellers offering these medicines without a prescription, often at prices well below the private market. You can report a suspect seller directly through the MHRA Yellow Card scheme.

After a significant list-price increase, the temptation to find a bargain is understandable, and our overview of the Mounjaro price increase in 2025 explains what's behind that shift and what it means for patients weighing up their options. For a prescription medicine, the cheapest listing answers the wrong question. The right question is whether the supply chain is licensed, whether a real clinician assessed your suitability, and whether you'd have support if something went wrong. Verifying any online pharmacy takes about sixty seconds on the GPhC register, it's one of the most useful checks you can do. If you have questions about the process before starting, our FAQs cover the most common ones, and students wondering whether reduced pricing is available can find the details on our Mounjaro student discount page. Our about page explains how our pharmacy and clinical model work.